The small molecule API market is expected to generate US$ 116 billion in 2023. Small molecule API market revenue is expected to reach US$ 174 billion by 2033. A CAGR of 4.1% is expected for the small molecule API market during the forecast period.
Attributes | Key Insights |
---|---|
Small Molecule API Market Value in 2023 | US$ 116 billion |
Projected Industry Value in 2033 | US$ 174 billion |
Value-based CAGR from 2023 to 2033 | 4.1% |
Small Molecule API Trends and Highlights
A trend toward personalized medicine has impacted the development of small-molecule APIs. Due to advances in genomics and targeted therapies, demand for small molecule API is growing. APIs are increasingly being designed based on genetic profiles and disease characteristics.
As oncology drugs and other therapies have developed, the demand for HPAPIs has increased owing to their high level of containment requirements to ensure the safety of both patients and workers. To produce HPAPIs, specialized equipment and facilities are required.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market was valued at US$ 110.3 billion in 2022. The market exhibited a CAGR of 5.20% between 2018 and 2022. A 4.1% CAGR is expected for small molecule API from 2023 to 2033. Pharmaceutical companies are adopting data analytics and digital technologies to enhance quality assurance, process control, and production efficiency.
Over the past two quarters, startups have benefited from funding and policies that facilitate their entry into the market. Several technologies are being developed for delivering medications in the molecule form over a long period. As a result, the small molecule API market is expected to continue growing steadily.
Companies increasingly use APIs to innovate and remain competitive in an ever-evolving technological environment. The synthetic chemistry community is under increasing pressure to create more potent, targeted, and complex molecules to find cost-effective and sustainable ways to develop their drug candidates.
Attributes | Details |
---|---|
H CAGR from 2018 to 2022 | 5.20% |
F CAGR from 2023 to 2033 | 4.1% |
Small molecules contribute to the production of many advanced materials, such as polymers, coatings, and specialty chemicals. Increasingly advanced materials science and the emergence of new applications are driving the small molecule API market. Specialty chemicals are widely used in many industries, such as electronics, adhesives, and cosmetics.
With diseases like cancer, cardiovascular disease, and infections on the rise, the small molecule API market continues to expand. Manufacturing companies involved in small molecule APIs have benefited greatly from this development. Agrochemicals and pharmaceuticals face strict regulatory requirements and safety standards, so small molecules are required to meet these standards.
The upcoming patent expirations of the most popular pharmaceuticals are driving the growth of the small molecule API market. APIs derived from small molecules have shown to be beneficial to one-third of the world's population in recent years. Technological advancements in the pharmaceutical industry are driving the growth of the small molecule API market.
The growing middle-class population in emerging economies is leading to an increase in the demand for small molecule API market expansion. Molecular discovery and development are made more efficient by advances in technologies such as high-throughput screening and combinatorial chemistry.
The use of small molecules in combination with biologics or other therapies for synergistic effects is a growing trend in the pharmaceutical industry. Individual patients' genetic and molecular markers are targeted with small molecule drugs as part of the trend toward personalized medicine.
APIs for small molecules are highly regulated in the pharmaceutical industry. The time and cost it takes to meet these requirements may encourage new players to enter the market, which could adversely affect the overall growth of the industry. With so many manufacturers and suppliers in the market, small molecule APIs are subject to intense price competition.
As a result, companies might have trouble maintaining profitability. Pharmaceutical manufacturing is increasingly focused on reducing its environmental impact. API production can be made more complicated and costly by complying with environmental regulations and adopting greener manufacturing processes.
Patents that give them exclusivity often protect APIs with small molecules. APIs using small molecules must be of high quality, safe, and consistent. Regulatory changes may negatively impact market growth, recalls, and brand reputation if quality standards are not met or safety concerns are not addressed. In clinical trials, small molecule APIs have a high failure rate because of the high cost of research and development. Investing heavily in research and development and assuming the risk of not being reimbursed can present major problems for companies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Future Market Insights explored two additional markets, namely the antibiotics active pharmaceutical ingredient (API) market and the small molecule innovator CDMO market. These two industries are expected to be dominated by small molecule APIs between 2023 and 2033.
Small Molecule API Market:
Attributes | Small Molecule API Market |
---|---|
Anticipated CAGR from 2023 to 2033 | 4.1% |
Market Value in 2023 | US$ 116 billion |
Growth Factor | A growing demand for drug development and the adoption of new technologies will drive the market in the decades to come. |
Opportunity | The emergence of new market entrants and the need for effective regulatory policies to make opportunities feasible. |
Antibiotics Active Pharmaceutical Ingredient (API) Market:
Attributes | Antibiotics Active Pharmaceutical Ingredient (API) Market |
---|---|
Anticipated CAGR from 2023 to 2033 | 3.3% |
Market Value in 2023 | US$ 8,653 million |
Growth Factor | As pharmaceutical manufacturing becomes more environmentally conscious, demand is expected to grow. |
Future Opportunities | Rising research and development activities and innovation in drug development to provide opportunities. |
Small Molecule Innovator CDMO Market:
Attributes | Small Molecule Innovator CDMO Market |
---|---|
Anticipated CAGR from 2023 to 2033 | 6.4% |
Estimated Value in 2023 | US$ 48.09 billion |
Growth Factor | Drug development and manufacturing outsourcing are increasing in demand as small-molecule drugs become increasingly popular. |
Future Opportunities | Small molecules are cheaper than biological drugs. Thus, the market is expected to grow as people seek out cost-effective drugs. |
The following table shows the top five revenue-generating countries, led by China and India. Increasing technologies and healthcare industries will contribute to the growth of small molecule API sales in the future. These two countries are expected to increase their small molecule API sales through 2033.
Forecast CAGRs of 2023 to 2033
Attributes | Details |
---|---|
China | 5.4% |
Germany | 2.5% |
India | 6.2% |
The United Kingdom | 2.7% |
The United States | 1.9% |
The United States is expected to grow rapidly in small molecule API during the assessment period. In 2033, the market is anticipated to increase by 1.9%. Increasing demand for effective pharmaceutical treatments drives the small molecule API industry in the United States. The treatment of these conditions can be significantly improved with small molecule APIs, which can target specific disease pathways.
Rising technological advancement and growing research and development activities drive the demand for small molecule API in the United States. Focusing on quality standards, technological advancements, and increased investment in research and development drives innovation and production of small molecule APIs.
India is expected to lead the small molecule API demand in the market. The market is expected to reach a 6.2% CAGR until 2033. Growing populations and chronic illnesses are expected to drive the market for small molecule APIs.
For instance, a profound transformation has occurred within the Indian pharmaceutical industry, from a generics-based economy to an industry based on innovation, largely due to Contract Development and Manufacturing Organizations (CDMOs). An annual report published by CPHI (Convention on Pharmaceutical Ingredients) reveals this paradigm shift.
Multinational pharmaceutical companies have set up production facilities in India owing to skilled labor, efficient manufacturing methods, and favorable regulatory policies, stimulating the small molecule API market.
The small molecule API market in China is expected to dominate until 2033. A 5.4% CAGR is estimated for the market until 2033. In addition to increased disease incidence, API manufacturing in China is growing. China has also become a leading manufacturer of small molecule APIs due to increased patient awareness and the presence of major players.
For instance, In March 2022, Lonza achieved its goal of focusing on high-potency APIs for small molecules by expanding the API manufacturing facility it operates in China. China's ability to manage waste products less strictly will continue to support growth. The development of the country's research and development facilities, as well as its social determination, are likely to support small molecules API market growth.
APIs for small molecules are becoming increasingly popular in Germany. A CAGR of 2.5% is anticipated from 2023 to 2033 for Germany. Growing incidences of health problems, coupled with an increase in pharmaceutical spending, are driving demand for pharmaceuticals in the country. A prevailing trend indicates that spending is expected to increase, which should lead to an increase in investments in small API molecules.
The United Kingdom will invest heavily in small molecule API technology in the coming years. The market is expected to expand at a CAGR of 2.7% by 2033. Various diseases and medical conditions can be treated with small molecule APIs. Their ability to target specific biological pathways or receptors allows them to be used for a wide variety of therapeutic purposes.
Tablets, creams, capsules, and injectables can be formulated with a variety of small molecule APIs, making them a versatile choice for various patient needs and preferences. The use of many small molecule APIs in healthcare has been approved through extensive research and clinical trials. As a result, they are certified as safe and effective. Hence, demand is expected to grow.
According to market forecasts, the standard API small molecule API segment will dominate with a 79.1% market share during the forecast period. According to the projection, the in-house segment is expected to hold a market share of 43.6%.
Attributes | Details |
---|---|
Standard API Market Share in 2023 | 79.1% |
In-House Market Share in 2023 | 43.6% |
Based on the molecule type, standard API is expected to dominate the market. Standard API is expected to hold 79.1% of the market share during the forecast period. Many diseases can be treated with small molecule APIs, which often drives the demand for these drugs.
Chronic conditions such as diabetes, cardiovascular disease, and hypertension, which require long-term treatment, typically have a consistent demand for APIs. With patent expirations of branded drugs, the generic API market may become more competitive, potentially increasing demand for APIs for small molecules.
Based on the production, the in-house segment will dominate the market. The in-house segment is expected to reach 43.6% market share by 2023. With the approval of increasingly complex molecules, outsourcing has been growing rapidly. As companies manufacture their own APIs, suppliers are less reliant on them. For instance, in September 2021, AstraZeneca announced a 360 million dollar investment in an Irish facility to manufacture APIs.
Companies operating across different geographies offer small molecule APIs globally. Major players in forming profitable alliances, and niche players or acquiring API companies to expand their global footprint are spending a lot of effort. Despite focusing on regional needs, domestic suppliers have product portfolios that are similar to those of international competitors.
Attributes | Details |
---|---|
Estimated Market Size in 2023 | US$ 116 billion |
Projected Market Valuation in 2033 | US$ 174 billion |
Value-based CAGR 2023 to 2033 | 4.1% |
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | Value in US$ billion |
Key Regions Covered |
|
Key Market Segments Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Small molecule API is expected to reach US$ 116 billion in 2023.
The small molecule API market is expected to increase by a CAGR of 4.1% by 2033.
The small molecule API is forecast to reach US$ 174 billion by 2033.
Standard API is expected to dominate the small molecule API market.
In-house production type is expected to dominate the small molecule API market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Molecule Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Molecule Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Molecule Type, 2023 to 2033 5.3.1. Standard API 5.3.2. HPAPI 5.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Molecule Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Production 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Production, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Production, 2023 to 2033 6.3.1. Captive/In-House 6.3.2. Outsourced 6.4. Y-o-Y Growth Trend Analysis By Production, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Production, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Application , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application , 2023 to 2033 7.3.1. Clinical 7.3.2. Commercial 7.4. Y-o-Y Growth Trend Analysis By Application , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Application , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033 8.3.1. Cardiovascular Diseases 8.3.2. Respiratory Disorders 8.3.3. Infectious Diseases 8.3.4. Metabolic Disorders 8.3.5. Oncology 8.3.6. Immunology 8.3.7. Neurology 8.3.8. Urology 8.3.9. Dermatology 8.3.10. Ophthalmology 8.3.11. General Health 8.3.12. Others 8.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Molecule Type 10.2.3. By Production 10.2.4. By Application 10.2.5. By Therapeutic Area 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Molecule Type 10.3.3. By Production 10.3.4. By Application 10.3.5. By Therapeutic Area 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Molecule Type 11.2.3. By Production 11.2.4. By Application 11.2.5. By Therapeutic Area 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Molecule Type 11.3.3. By Production 11.3.4. By Application 11.3.5. By Therapeutic Area 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Molecule Type 12.2.3. By Production 12.2.4. By Application 12.2.5. By Therapeutic Area 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Molecule Type 12.3.3. By Production 12.3.4. By Application 12.3.5. By Therapeutic Area 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Molecule Type 13.2.3. By Production 13.2.4. By Application 13.2.5. By Therapeutic Area 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Molecule Type 13.3.3. By Production 13.3.4. By Application 13.3.5. By Therapeutic Area 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Molecule Type 14.2.3. By Production 14.2.4. By Application 14.2.5. By Therapeutic Area 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Molecule Type 14.3.3. By Production 14.3.4. By Application 14.3.5. By Therapeutic Area 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Molecule Type 15.2.3. By Production 15.2.4. By Application 15.2.5. By Therapeutic Area 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Molecule Type 15.3.3. By Production 15.3.4. By Application 15.3.5. By Therapeutic Area 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Molecule Type 16.2.3. By Production 16.2.4. By Application 16.2.5. By Therapeutic Area 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Molecule Type 16.3.3. By Production 16.3.4. By Application 16.3.5. By Therapeutic Area 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2023 17.1.2.1. By Molecule Type 17.1.2.2. By Production 17.1.2.3. By Application 17.1.2.4. By Therapeutic Area 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2023 17.2.2.1. By Molecule Type 17.2.2.2. By Production 17.2.2.3. By Application 17.2.2.4. By Therapeutic Area 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2023 17.3.2.1. By Molecule Type 17.3.2.2. By Production 17.3.2.3. By Application 17.3.2.4. By Therapeutic Area 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2023 17.4.2.1. By Molecule Type 17.4.2.2. By Production 17.4.2.3. By Application 17.4.2.4. By Therapeutic Area 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2023 17.5.2.1. By Molecule Type 17.5.2.2. By Production 17.5.2.3. By Application 17.5.2.4. By Therapeutic Area 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2023 17.6.2.1. By Molecule Type 17.6.2.2. By Production 17.6.2.3. By Application 17.6.2.4. By Therapeutic Area 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2023 17.7.2.1. By Molecule Type 17.7.2.2. By Production 17.7.2.3. By Application 17.7.2.4. By Therapeutic Area 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2023 17.8.2.1. By Molecule Type 17.8.2.2. By Production 17.8.2.3. By Application 17.8.2.4. By Therapeutic Area 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2023 17.9.2.1. By Molecule Type 17.9.2.2. By Production 17.9.2.3. By Application 17.9.2.4. By Therapeutic Area 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2023 17.10.2.1. By Molecule Type 17.10.2.2. By Production 17.10.2.3. By Application 17.10.2.4. By Therapeutic Area 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2023 17.11.2.1. By Molecule Type 17.11.2.2. By Production 17.11.2.3. By Application 17.11.2.4. By Therapeutic Area 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2023 17.12.2.1. By Molecule Type 17.12.2.2. By Production 17.12.2.3. By Application 17.12.2.4. By Therapeutic Area 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2023 17.13.2.1. By Molecule Type 17.13.2.2. By Production 17.13.2.3. By Application 17.13.2.4. By Therapeutic Area 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2023 17.14.2.1. By Molecule Type 17.14.2.2. By Production 17.14.2.3. By Application 17.14.2.4. By Therapeutic Area 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2023 17.15.2.1. By Molecule Type 17.15.2.2. By Production 17.15.2.3. By Application 17.15.2.4. By Therapeutic Area 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2023 17.16.2.1. By Molecule Type 17.16.2.2. By Production 17.16.2.3. By Application 17.16.2.4. By Therapeutic Area 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2023 17.17.2.1. By Molecule Type 17.17.2.2. By Production 17.17.2.3. By Application 17.17.2.4. By Therapeutic Area 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2023 17.18.2.1. By Molecule Type 17.18.2.2. By Production 17.18.2.3. By Application 17.18.2.4. By Therapeutic Area 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2023 17.19.2.1. By Molecule Type 17.19.2.2. By Production 17.19.2.3. By Application 17.19.2.4. By Therapeutic Area 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2023 17.20.2.1. By Molecule Type 17.20.2.2. By Production 17.20.2.3. By Application 17.20.2.4. By Therapeutic Area 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2023 17.21.2.1. By Molecule Type 17.21.2.2. By Production 17.21.2.3. By Application 17.21.2.4. By Therapeutic Area 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2023 17.22.2.1. By Molecule Type 17.22.2.2. By Production 17.22.2.3. By Application 17.22.2.4. By Therapeutic Area 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2023 17.23.2.1. By Molecule Type 17.23.2.2. By Production 17.23.2.3. By Application 17.23.2.4. By Therapeutic Area 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Molecule Type 18.3.3. By Production 18.3.4. By Application 18.3.5. By Therapeutic Area 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Johnson Matthey 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Pfizer Inc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Sanofi S.A 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Novartis AG 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Bristol-Myers Squibb 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Boehringer Ingelheim GmbH 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. GlaxoSmithKline PLC 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. GILEAD Sciences Inc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Albany Molecular Research Inc. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Healthcare
June 2020
REP-GB-1719
October 2023
333 pages
Healthcare
February 2021
REP-GB-13025
June 2023
273 pages
Explore Healthcare Insights
View Reports